Skin Cancer Test Maker DermTech Files Bankruptcy to Sell Assets

DermTech Inc., a publicly traded developer of a non-invasive skin cancer test, has filed for bankruptcy in order to sell its assets.

• San Diego-based DermTech listed assets and liabilities each of between $50 million and $100 million in a Chapter 11 petition filed Tuesday in Delaware bankruptcy court
• The company said in a press release that it intends to continue its laboratory operations and continue processing orders of its DermTech melanoma test while marketing its assets for sale in Chapter 11
  • DermTech has retained TD Cowen as investment banker and AlixPartners LLP as restructuring and financial adviser, according to ...